Sanofi India Limited (BOM:500674)
Market Cap | 141.92B |
Revenue (ttm) | 20.13B |
Net Income (ttm) | 4.13B |
Shares Out | 23.03M |
EPS (ttm) | 179.46 |
PE Ratio | 45.24 |
Forward PE | 31.76 |
Dividend | 117.00 (1.89%) |
Ex-Dividend Date | Apr 25, 2025 |
Volume | 143 |
Average Volume | 619 |
Open | 6,193.90 |
Previous Close | 6,172.80 |
Day's Range | 6,131.00 - 6,216.80 |
52-Week Range | 4,145.90 - 10,526.05 |
Beta | 0.07 |
RSI | 51.18 |
Earnings Date | Jul 25, 2025 |
About Sanofi India
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAS... [Read more]
Financial Performance
In 2024, Sanofi India's revenue was 20.13 billion, an increase of 0.86% compared to the previous year's 19.96 billion. Earnings were 4.13 billion, a decrease of -31.45%.
Financial StatementsNews

Sanofi India shares jumpo over 2% following Q4 FY25 Results
Sanofi India reported a mixed set of numbers for the March quarter, with a notable improvement in operational performance offsetting a decline in net profit. For Q4 FY25, net profit fell 12.5% year-on...

Sanofi India shares surge 6% on Q4 results; Rs 117 final dividend recommendation
Sanofi India Ltd. saw a strong uptick in its stock price on Friday, rising 6.04% to ₹5,288.30, following the announcement of its Q4 financial results. The stock traded within a day range of ₹5,009.00 ...

Sanofi India Recommends Rs 117 per share final dividend for Q4
Sanofi India Limited has recommended a final dividend of ₹117 per equity share of face value ₹10 for the financial year ended December 31, 2024. The dividend is subject to approval at the 69th Annual ...

Sanofi India Q4 Results: Net Profit declines 33.7% YoY, Revenue up 9.7% to Rs 514.9 crore
Sanofi India Limited has announced its Q4 financial results, reporting a 33.7% YoY decline in net profit to ₹91.3 crore, compared to ₹137.7 crore in the same period last year. Meanwhile, revenue incre...

Stocks hitting 52-week low today, February 21: Sanofi India, Tata Communications, Star Health and more
The Indian stock market continued its downward trend for the fourth consecutive session on February 21, 2024. Both the Sensex and Nifty 50 ended in negative territory, reflecting bearish investor sent...

52 week low stocks today on January 21: MRF, Axis Bank, Sanofi India, Sterling, EaseMyTrip and more
On January 21, 2025, the Indian stock market saw a significant downturn, with both the BSE Sensex and Nifty 50 indices closing in the red. The BSE Sensex plunged 1,235.08 points, or 1.60%, finishing a...
Sanofi Consumer makes its debut on stock exchanges
Sanofi Consumer Healthcare has been listed on the BSE and NSE after its demerger from Sanofi India. Approved by the National Company Law Tribunal, this move aligns with Sanofi's global strategy. The c...